Global Metabolic Disorder Therapeutics Market Growth (Status and Outlook) 2025-2031
According to this study, the global Metabolic Disorder Therapeutics market size will reach US$ 68770 million by 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Metabolic Disorder Therapeutics Industry Forecast” looks at past sales and reviews total world Metabolic Disorder Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Metabolic Disorder Therapeutics sales for 2025 through 2031. With Metabolic Disorder Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Metabolic Disorder Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Metabolic Disorder Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Metabolic Disorder Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Metabolic Disorder Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Metabolic Disorder Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Metabolic Disorder Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Metabolic Disorder Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Metabolic Disorder Therapeutics Industry Forecast” looks at past sales and reviews total world Metabolic Disorder Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Metabolic Disorder Therapeutics sales for 2025 through 2031. With Metabolic Disorder Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Metabolic Disorder Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Metabolic Disorder Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Metabolic Disorder Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Metabolic Disorder Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Metabolic Disorder Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Metabolic Disorder Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Metabolic Disorder Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Lysosomal Storage Diseases
- Diabetes
- Obesity
- Inherited Metabolic Disorders
- Hypercholesterolemia
- Oral
- Parenteral
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novo Nordisk A/S
- Sanofi S.A.
- Boehringer Ingelheim GmbH
- Eli Lilly and Company
- Merck KgaA
- Amgen, Inc.
- AstraZeneca PLC
- Actelion Pharmaceuticals Ltd.
- Shire PLC
- AbbVie, Inc.
- Biocon Ltd.
- BioMarin Pharmaceutical, Inc.
- Bristol-Myers Squibb Company
- Cipla, Inc.
- CymaBay Therapeutics, Inc.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Metabolic Disorder Therapeutics Market Size (2020-2031)
2.1.2 Metabolic Disorder Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Metabolic Disorder Therapeutics by Country/Region (2020, 2024 & 2031)
2.2 Metabolic Disorder Therapeutics Segment by Type
2.2.1 Lysosomal Storage Diseases
2.2.2 Diabetes
2.2.3 Obesity
2.2.4 Inherited Metabolic Disorders
2.2.5 Hypercholesterolemia
2.3 Metabolic Disorder Therapeutics Market Size by Type
2.3.1 Metabolic Disorder Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
2.4 Metabolic Disorder Therapeutics Segment by Application
2.4.1 Oral
2.4.2 Parenteral
2.4.3 Others
2.5 Metabolic Disorder Therapeutics Market Size by Application
2.5.1 Metabolic Disorder Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
3 METABOLIC DISORDER THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Metabolic Disorder Therapeutics Market Size Market Share by Player
3.1.1 Global Metabolic Disorder Therapeutics Revenue by Player (2020-2025)
3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Player (2020-2025)
3.2 Global Metabolic Disorder Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 METABOLIC DISORDER THERAPEUTICS BY REGION
4.1 Metabolic Disorder Therapeutics Market Size by Region (2020-2025)
4.2 Global Metabolic Disorder Therapeutics Annual Revenue by Country/Region (2020-2025)
4.3 Americas Metabolic Disorder Therapeutics Market Size Growth (2020-2025)
4.4 APAC Metabolic Disorder Therapeutics Market Size Growth (2020-2025)
4.5 Europe Metabolic Disorder Therapeutics Market Size Growth (2020-2025)
4.6 Middle East & Africa Metabolic Disorder Therapeutics Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Metabolic Disorder Therapeutics Market Size by Country (2020-2025)
5.2 Americas Metabolic Disorder Therapeutics Market Size by Type (2020-2025)
5.3 Americas Metabolic Disorder Therapeutics Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Metabolic Disorder Therapeutics Market Size by Region (2020-2025)
6.2 APAC Metabolic Disorder Therapeutics Market Size by Type (2020-2025)
6.3 APAC Metabolic Disorder Therapeutics Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Metabolic Disorder Therapeutics Market Size by Country (2020-2025)
7.2 Europe Metabolic Disorder Therapeutics Market Size by Type (2020-2025)
7.3 Europe Metabolic Disorder Therapeutics Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Metabolic Disorder Therapeutics by Region (2020-2025)
8.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2020-2025)
8.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET FORECAST
10.1 Global Metabolic Disorder Therapeutics Forecast by Region (2026-2031)
10.1.1 Global Metabolic Disorder Therapeutics Forecast by Region (2026-2031)
10.1.2 Americas Metabolic Disorder Therapeutics Forecast
10.1.3 APAC Metabolic Disorder Therapeutics Forecast
10.1.4 Europe Metabolic Disorder Therapeutics Forecast
10.1.5 Middle East & Africa Metabolic Disorder Therapeutics Forecast
10.2 Americas Metabolic Disorder Therapeutics Forecast by Country (2026-2031)
10.2.1 United States Market Metabolic Disorder Therapeutics Forecast
10.2.2 Canada Market Metabolic Disorder Therapeutics Forecast
10.2.3 Mexico Market Metabolic Disorder Therapeutics Forecast
10.2.4 Brazil Market Metabolic Disorder Therapeutics Forecast
10.3 APAC Metabolic Disorder Therapeutics Forecast by Region (2026-2031)
10.3.1 China Metabolic Disorder Therapeutics Market Forecast
10.3.2 Japan Market Metabolic Disorder Therapeutics Forecast
10.3.3 Korea Market Metabolic Disorder Therapeutics Forecast
10.3.4 Southeast Asia Market Metabolic Disorder Therapeutics Forecast
10.3.5 India Market Metabolic Disorder Therapeutics Forecast
10.3.6 Australia Market Metabolic Disorder Therapeutics Forecast
10.4 Europe Metabolic Disorder Therapeutics Forecast by Country (2026-2031)
10.4.1 Germany Market Metabolic Disorder Therapeutics Forecast
10.4.2 France Market Metabolic Disorder Therapeutics Forecast
10.4.3 UK Market Metabolic Disorder Therapeutics Forecast
10.4.4 Italy Market Metabolic Disorder Therapeutics Forecast
10.4.5 Russia Market Metabolic Disorder Therapeutics Forecast
10.5 Middle East & Africa Metabolic Disorder Therapeutics Forecast by Region (2026-2031)
10.5.1 Egypt Market Metabolic Disorder Therapeutics Forecast
10.5.2 South Africa Market Metabolic Disorder Therapeutics Forecast
10.5.3 Israel Market Metabolic Disorder Therapeutics Forecast
10.5.4 Turkey Market Metabolic Disorder Therapeutics Forecast
10.6 Global Metabolic Disorder Therapeutics Forecast by Type (2026-2031)
10.7 Global Metabolic Disorder Therapeutics Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Metabolic Disorder Therapeutics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novo Nordisk A/S
11.1.1 Novo Nordisk A/S Company Information
11.1.2 Novo Nordisk A/S Metabolic Disorder Therapeutics Product Offered
11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Novo Nordisk A/S Main Business Overview
11.1.5 Novo Nordisk A/S Latest Developments
11.2 Sanofi S.A.
11.2.1 Sanofi S.A. Company Information
11.2.2 Sanofi S.A. Metabolic Disorder Therapeutics Product Offered
11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Sanofi S.A. Main Business Overview
11.2.5 Sanofi S.A. Latest Developments
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Information
11.3.2 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product Offered
11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Boehringer Ingelheim GmbH Main Business Overview
11.3.5 Boehringer Ingelheim GmbH Latest Developments
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Information
11.4.2 Eli Lilly and Company Metabolic Disorder Therapeutics Product Offered
11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Eli Lilly and Company Main Business Overview
11.4.5 Eli Lilly and Company Latest Developments
11.5 Merck KgaA
11.5.1 Merck KgaA Company Information
11.5.2 Merck KgaA Metabolic Disorder Therapeutics Product Offered
11.5.3 Merck KgaA Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Merck KgaA Main Business Overview
11.5.5 Merck KgaA Latest Developments
11.6 Amgen, Inc.
11.6.1 Amgen, Inc. Company Information
11.6.2 Amgen, Inc. Metabolic Disorder Therapeutics Product Offered
11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Amgen, Inc. Main Business Overview
11.6.5 Amgen, Inc. Latest Developments
11.7 AstraZeneca PLC
11.7.1 AstraZeneca PLC Company Information
11.7.2 AstraZeneca PLC Metabolic Disorder Therapeutics Product Offered
11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 AstraZeneca PLC Main Business Overview
11.7.5 AstraZeneca PLC Latest Developments
11.8 Actelion Pharmaceuticals Ltd.
11.8.1 Actelion Pharmaceuticals Ltd. Company Information
11.8.2 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product Offered
11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Actelion Pharmaceuticals Ltd. Main Business Overview
11.8.5 Actelion Pharmaceuticals Ltd. Latest Developments
11.9 Shire PLC
11.9.1 Shire PLC Company Information
11.9.2 Shire PLC Metabolic Disorder Therapeutics Product Offered
11.9.3 Shire PLC Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Shire PLC Main Business Overview
11.9.5 Shire PLC Latest Developments
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Information
11.10.2 AbbVie, Inc. Metabolic Disorder Therapeutics Product Offered
11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 AbbVie, Inc. Main Business Overview
11.10.5 AbbVie, Inc. Latest Developments
11.11 Biocon Ltd.
11.11.1 Biocon Ltd. Company Information
11.11.2 Biocon Ltd. Metabolic Disorder Therapeutics Product Offered
11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Biocon Ltd. Main Business Overview
11.11.5 Biocon Ltd. Latest Developments
11.12 BioMarin Pharmaceutical, Inc.
11.12.1 BioMarin Pharmaceutical, Inc. Company Information
11.12.2 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product Offered
11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 BioMarin Pharmaceutical, Inc. Main Business Overview
11.12.5 BioMarin Pharmaceutical, Inc. Latest Developments
11.13 Bristol-Myers Squibb Company
11.13.1 Bristol-Myers Squibb Company Company Information
11.13.2 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product Offered
11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Bristol-Myers Squibb Company Main Business Overview
11.13.5 Bristol-Myers Squibb Company Latest Developments
11.14 Cipla, Inc.
11.14.1 Cipla, Inc. Company Information
11.14.2 Cipla, Inc. Metabolic Disorder Therapeutics Product Offered
11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Cipla, Inc. Main Business Overview
11.14.5 Cipla, Inc. Latest Developments
11.15 CymaBay Therapeutics, Inc.
11.15.1 CymaBay Therapeutics, Inc. Company Information
11.15.2 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product Offered
11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 CymaBay Therapeutics, Inc. Main Business Overview
11.15.5 CymaBay Therapeutics, Inc. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Metabolic Disorder Therapeutics Market Size (2020-2031)
2.1.2 Metabolic Disorder Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Metabolic Disorder Therapeutics by Country/Region (2020, 2024 & 2031)
2.2 Metabolic Disorder Therapeutics Segment by Type
2.2.1 Lysosomal Storage Diseases
2.2.2 Diabetes
2.2.3 Obesity
2.2.4 Inherited Metabolic Disorders
2.2.5 Hypercholesterolemia
2.3 Metabolic Disorder Therapeutics Market Size by Type
2.3.1 Metabolic Disorder Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
2.4 Metabolic Disorder Therapeutics Segment by Application
2.4.1 Oral
2.4.2 Parenteral
2.4.3 Others
2.5 Metabolic Disorder Therapeutics Market Size by Application
2.5.1 Metabolic Disorder Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
3 METABOLIC DISORDER THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Metabolic Disorder Therapeutics Market Size Market Share by Player
3.1.1 Global Metabolic Disorder Therapeutics Revenue by Player (2020-2025)
3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Player (2020-2025)
3.2 Global Metabolic Disorder Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 METABOLIC DISORDER THERAPEUTICS BY REGION
4.1 Metabolic Disorder Therapeutics Market Size by Region (2020-2025)
4.2 Global Metabolic Disorder Therapeutics Annual Revenue by Country/Region (2020-2025)
4.3 Americas Metabolic Disorder Therapeutics Market Size Growth (2020-2025)
4.4 APAC Metabolic Disorder Therapeutics Market Size Growth (2020-2025)
4.5 Europe Metabolic Disorder Therapeutics Market Size Growth (2020-2025)
4.6 Middle East & Africa Metabolic Disorder Therapeutics Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Metabolic Disorder Therapeutics Market Size by Country (2020-2025)
5.2 Americas Metabolic Disorder Therapeutics Market Size by Type (2020-2025)
5.3 Americas Metabolic Disorder Therapeutics Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Metabolic Disorder Therapeutics Market Size by Region (2020-2025)
6.2 APAC Metabolic Disorder Therapeutics Market Size by Type (2020-2025)
6.3 APAC Metabolic Disorder Therapeutics Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Metabolic Disorder Therapeutics Market Size by Country (2020-2025)
7.2 Europe Metabolic Disorder Therapeutics Market Size by Type (2020-2025)
7.3 Europe Metabolic Disorder Therapeutics Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Metabolic Disorder Therapeutics by Region (2020-2025)
8.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2020-2025)
8.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET FORECAST
10.1 Global Metabolic Disorder Therapeutics Forecast by Region (2026-2031)
10.1.1 Global Metabolic Disorder Therapeutics Forecast by Region (2026-2031)
10.1.2 Americas Metabolic Disorder Therapeutics Forecast
10.1.3 APAC Metabolic Disorder Therapeutics Forecast
10.1.4 Europe Metabolic Disorder Therapeutics Forecast
10.1.5 Middle East & Africa Metabolic Disorder Therapeutics Forecast
10.2 Americas Metabolic Disorder Therapeutics Forecast by Country (2026-2031)
10.2.1 United States Market Metabolic Disorder Therapeutics Forecast
10.2.2 Canada Market Metabolic Disorder Therapeutics Forecast
10.2.3 Mexico Market Metabolic Disorder Therapeutics Forecast
10.2.4 Brazil Market Metabolic Disorder Therapeutics Forecast
10.3 APAC Metabolic Disorder Therapeutics Forecast by Region (2026-2031)
10.3.1 China Metabolic Disorder Therapeutics Market Forecast
10.3.2 Japan Market Metabolic Disorder Therapeutics Forecast
10.3.3 Korea Market Metabolic Disorder Therapeutics Forecast
10.3.4 Southeast Asia Market Metabolic Disorder Therapeutics Forecast
10.3.5 India Market Metabolic Disorder Therapeutics Forecast
10.3.6 Australia Market Metabolic Disorder Therapeutics Forecast
10.4 Europe Metabolic Disorder Therapeutics Forecast by Country (2026-2031)
10.4.1 Germany Market Metabolic Disorder Therapeutics Forecast
10.4.2 France Market Metabolic Disorder Therapeutics Forecast
10.4.3 UK Market Metabolic Disorder Therapeutics Forecast
10.4.4 Italy Market Metabolic Disorder Therapeutics Forecast
10.4.5 Russia Market Metabolic Disorder Therapeutics Forecast
10.5 Middle East & Africa Metabolic Disorder Therapeutics Forecast by Region (2026-2031)
10.5.1 Egypt Market Metabolic Disorder Therapeutics Forecast
10.5.2 South Africa Market Metabolic Disorder Therapeutics Forecast
10.5.3 Israel Market Metabolic Disorder Therapeutics Forecast
10.5.4 Turkey Market Metabolic Disorder Therapeutics Forecast
10.6 Global Metabolic Disorder Therapeutics Forecast by Type (2026-2031)
10.7 Global Metabolic Disorder Therapeutics Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Metabolic Disorder Therapeutics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novo Nordisk A/S
11.1.1 Novo Nordisk A/S Company Information
11.1.2 Novo Nordisk A/S Metabolic Disorder Therapeutics Product Offered
11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Novo Nordisk A/S Main Business Overview
11.1.5 Novo Nordisk A/S Latest Developments
11.2 Sanofi S.A.
11.2.1 Sanofi S.A. Company Information
11.2.2 Sanofi S.A. Metabolic Disorder Therapeutics Product Offered
11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Sanofi S.A. Main Business Overview
11.2.5 Sanofi S.A. Latest Developments
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Information
11.3.2 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product Offered
11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Boehringer Ingelheim GmbH Main Business Overview
11.3.5 Boehringer Ingelheim GmbH Latest Developments
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Information
11.4.2 Eli Lilly and Company Metabolic Disorder Therapeutics Product Offered
11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Eli Lilly and Company Main Business Overview
11.4.5 Eli Lilly and Company Latest Developments
11.5 Merck KgaA
11.5.1 Merck KgaA Company Information
11.5.2 Merck KgaA Metabolic Disorder Therapeutics Product Offered
11.5.3 Merck KgaA Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Merck KgaA Main Business Overview
11.5.5 Merck KgaA Latest Developments
11.6 Amgen, Inc.
11.6.1 Amgen, Inc. Company Information
11.6.2 Amgen, Inc. Metabolic Disorder Therapeutics Product Offered
11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Amgen, Inc. Main Business Overview
11.6.5 Amgen, Inc. Latest Developments
11.7 AstraZeneca PLC
11.7.1 AstraZeneca PLC Company Information
11.7.2 AstraZeneca PLC Metabolic Disorder Therapeutics Product Offered
11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 AstraZeneca PLC Main Business Overview
11.7.5 AstraZeneca PLC Latest Developments
11.8 Actelion Pharmaceuticals Ltd.
11.8.1 Actelion Pharmaceuticals Ltd. Company Information
11.8.2 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product Offered
11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Actelion Pharmaceuticals Ltd. Main Business Overview
11.8.5 Actelion Pharmaceuticals Ltd. Latest Developments
11.9 Shire PLC
11.9.1 Shire PLC Company Information
11.9.2 Shire PLC Metabolic Disorder Therapeutics Product Offered
11.9.3 Shire PLC Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Shire PLC Main Business Overview
11.9.5 Shire PLC Latest Developments
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Information
11.10.2 AbbVie, Inc. Metabolic Disorder Therapeutics Product Offered
11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 AbbVie, Inc. Main Business Overview
11.10.5 AbbVie, Inc. Latest Developments
11.11 Biocon Ltd.
11.11.1 Biocon Ltd. Company Information
11.11.2 Biocon Ltd. Metabolic Disorder Therapeutics Product Offered
11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Biocon Ltd. Main Business Overview
11.11.5 Biocon Ltd. Latest Developments
11.12 BioMarin Pharmaceutical, Inc.
11.12.1 BioMarin Pharmaceutical, Inc. Company Information
11.12.2 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product Offered
11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 BioMarin Pharmaceutical, Inc. Main Business Overview
11.12.5 BioMarin Pharmaceutical, Inc. Latest Developments
11.13 Bristol-Myers Squibb Company
11.13.1 Bristol-Myers Squibb Company Company Information
11.13.2 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product Offered
11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Bristol-Myers Squibb Company Main Business Overview
11.13.5 Bristol-Myers Squibb Company Latest Developments
11.14 Cipla, Inc.
11.14.1 Cipla, Inc. Company Information
11.14.2 Cipla, Inc. Metabolic Disorder Therapeutics Product Offered
11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Cipla, Inc. Main Business Overview
11.14.5 Cipla, Inc. Latest Developments
11.15 CymaBay Therapeutics, Inc.
11.15.1 CymaBay Therapeutics, Inc. Company Information
11.15.2 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product Offered
11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 CymaBay Therapeutics, Inc. Main Business Overview
11.15.5 CymaBay Therapeutics, Inc. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Metabolic Disorder Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Metabolic Disorder Therapeutics Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Lysosomal Storage Diseases
Table 4. Major Players of Diabetes
Table 5. Major Players of Obesity
Table 6. Major Players of Inherited Metabolic Disorders
Table 7. Major Players of Hypercholesterolemia
Table 8. Metabolic Disorder Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & ($ millions)
Table 10. Global Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
Table 11. Metabolic Disorder Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 12. Global Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 13. Global Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
Table 14. Global Metabolic Disorder Therapeutics Revenue by Player (2020-2025) & ($ millions)
Table 15. Global Metabolic Disorder Therapeutics Revenue Market Share by Player (2020-2025)
Table 16. Metabolic Disorder Therapeutics Key Players Head office and Products Offered
Table 17. Metabolic Disorder Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Metabolic Disorder Therapeutics Market Size by Region (2020-2025) & ($ millions)
Table 21. Global Metabolic Disorder Therapeutics Market Size Market Share by Region (2020-2025)
Table 22. Global Metabolic Disorder Therapeutics Revenue by Country/Region (2020-2025) & ($ millions)
Table 23. Global Metabolic Disorder Therapeutics Revenue Market Share by Country/Region (2020-2025)
Table 24. Americas Metabolic Disorder Therapeutics Market Size by Country (2020-2025) & ($ millions)
Table 25. Americas Metabolic Disorder Therapeutics Market Size Market Share by Country (2020-2025)
Table 26. Americas Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & ($ millions)
Table 27. Americas Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
Table 28. Americas Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 29. Americas Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
Table 30. APAC Metabolic Disorder Therapeutics Market Size by Region (2020-2025) & ($ millions)
Table 31. APAC Metabolic Disorder Therapeutics Market Size Market Share by Region (2020-2025)
Table 32. APAC Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & ($ millions)
Table 33. APAC Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 34. Europe Metabolic Disorder Therapeutics Market Size by Country (2020-2025) & ($ millions)
Table 35. Europe Metabolic Disorder Therapeutics Market Size Market Share by Country (2020-2025)
Table 36. Europe Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & ($ millions)
Table 37. Europe Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 38. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Region (2020-2025) & ($ millions)
Table 39. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & ($ millions)
Table 40. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of Metabolic Disorder Therapeutics
Table 42. Key Market Challenges & Risks of Metabolic Disorder Therapeutics
Table 43. Key Industry Trends of Metabolic Disorder Therapeutics
Table 44. Global Metabolic Disorder Therapeutics Market Size Forecast by Region (2026-2031) & ($ millions)
Table 45. Global Metabolic Disorder Therapeutics Market Size Market Share Forecast by Region (2026-2031)
Table 46. Global Metabolic Disorder Therapeutics Market Size Forecast by Type (2026-2031) & ($ millions)
Table 47. Global Metabolic Disorder Therapeutics Market Size Forecast by Application (2026-2031) & ($ millions)
Table 48. Novo Nordisk A/S Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 49. Novo Nordisk A/S Metabolic Disorder Therapeutics Product Offered
Table 50. Novo Nordisk A/S Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 51. Novo Nordisk A/S Main Business
Table 52. Novo Nordisk A/S Latest Developments
Table 53. Sanofi S.A. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 54. Sanofi S.A. Metabolic Disorder Therapeutics Product Offered
Table 55. Sanofi S.A. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 56. Sanofi S.A. Main Business
Table 57. Sanofi S.A. Latest Developments
Table 58. Boehringer Ingelheim GmbH Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 59. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product Offered
Table 60. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 61. Boehringer Ingelheim GmbH Main Business
Table 62. Boehringer Ingelheim GmbH Latest Developments
Table 63. Eli Lilly and Company Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 64. Eli Lilly and Company Metabolic Disorder Therapeutics Product Offered
Table 65. Eli Lilly and Company Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 66. Eli Lilly and Company Main Business
Table 67. Eli Lilly and Company Latest Developments
Table 68. Merck KgaA Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 69. Merck KgaA Metabolic Disorder Therapeutics Product Offered
Table 70. Merck KgaA Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 71. Merck KgaA Main Business
Table 72. Merck KgaA Latest Developments
Table 73. Amgen, Inc. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 74. Amgen, Inc. Metabolic Disorder Therapeutics Product Offered
Table 75. Amgen, Inc. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 76. Amgen, Inc. Main Business
Table 77. Amgen, Inc. Latest Developments
Table 78. AstraZeneca PLC Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 79. AstraZeneca PLC Metabolic Disorder Therapeutics Product Offered
Table 80. AstraZeneca PLC Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 81. AstraZeneca PLC Main Business
Table 82. AstraZeneca PLC Latest Developments
Table 83. Actelion Pharmaceuticals Ltd. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 84. Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product Offered
Table 85. Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 86. Actelion Pharmaceuticals Ltd. Main Business
Table 87. Actelion Pharmaceuticals Ltd. Latest Developments
Table 88. Shire PLC Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 89. Shire PLC Metabolic Disorder Therapeutics Product Offered
Table 90. Shire PLC Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 91. Shire PLC Main Business
Table 92. Shire PLC Latest Developments
Table 93. AbbVie, Inc. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 94. AbbVie, Inc. Metabolic Disorder Therapeutics Product Offered
Table 95. AbbVie, Inc. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 96. AbbVie, Inc. Main Business
Table 97. AbbVie, Inc. Latest Developments
Table 98. Biocon Ltd. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 99. Biocon Ltd. Metabolic Disorder Therapeutics Product Offered
Table 100. Biocon Ltd. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 101. Biocon Ltd. Main Business
Table 102. Biocon Ltd. Latest Developments
Table 103. BioMarin Pharmaceutical, Inc. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 104. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product Offered
Table 105. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 106. BioMarin Pharmaceutical, Inc. Main Business
Table 107. BioMarin Pharmaceutical, Inc. Latest Developments
Table 108. Bristol-Myers Squibb Company Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 109. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product Offered
Table 110. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 111. Bristol-Myers Squibb Company Main Business
Table 112. Bristol-Myers Squibb Company Latest Developments
Table 113. Cipla, Inc. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 114. Cipla, Inc. Metabolic Disorder Therapeutics Product Offered
Table 115. Cipla, Inc. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 116. Cipla, Inc. Main Business
Table 117. Cipla, Inc. Latest Developments
Table 118. CymaBay Therapeutics, Inc. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 119. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product Offered
Table 120. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 121. CymaBay Therapeutics, Inc. Main Business
Table 122. CymaBay Therapeutics, Inc. Latest Developments
Table 1. Metabolic Disorder Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Metabolic Disorder Therapeutics Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Lysosomal Storage Diseases
Table 4. Major Players of Diabetes
Table 5. Major Players of Obesity
Table 6. Major Players of Inherited Metabolic Disorders
Table 7. Major Players of Hypercholesterolemia
Table 8. Metabolic Disorder Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & ($ millions)
Table 10. Global Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
Table 11. Metabolic Disorder Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 12. Global Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 13. Global Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
Table 14. Global Metabolic Disorder Therapeutics Revenue by Player (2020-2025) & ($ millions)
Table 15. Global Metabolic Disorder Therapeutics Revenue Market Share by Player (2020-2025)
Table 16. Metabolic Disorder Therapeutics Key Players Head office and Products Offered
Table 17. Metabolic Disorder Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Metabolic Disorder Therapeutics Market Size by Region (2020-2025) & ($ millions)
Table 21. Global Metabolic Disorder Therapeutics Market Size Market Share by Region (2020-2025)
Table 22. Global Metabolic Disorder Therapeutics Revenue by Country/Region (2020-2025) & ($ millions)
Table 23. Global Metabolic Disorder Therapeutics Revenue Market Share by Country/Region (2020-2025)
Table 24. Americas Metabolic Disorder Therapeutics Market Size by Country (2020-2025) & ($ millions)
Table 25. Americas Metabolic Disorder Therapeutics Market Size Market Share by Country (2020-2025)
Table 26. Americas Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & ($ millions)
Table 27. Americas Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
Table 28. Americas Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 29. Americas Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
Table 30. APAC Metabolic Disorder Therapeutics Market Size by Region (2020-2025) & ($ millions)
Table 31. APAC Metabolic Disorder Therapeutics Market Size Market Share by Region (2020-2025)
Table 32. APAC Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & ($ millions)
Table 33. APAC Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 34. Europe Metabolic Disorder Therapeutics Market Size by Country (2020-2025) & ($ millions)
Table 35. Europe Metabolic Disorder Therapeutics Market Size Market Share by Country (2020-2025)
Table 36. Europe Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & ($ millions)
Table 37. Europe Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 38. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Region (2020-2025) & ($ millions)
Table 39. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & ($ millions)
Table 40. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of Metabolic Disorder Therapeutics
Table 42. Key Market Challenges & Risks of Metabolic Disorder Therapeutics
Table 43. Key Industry Trends of Metabolic Disorder Therapeutics
Table 44. Global Metabolic Disorder Therapeutics Market Size Forecast by Region (2026-2031) & ($ millions)
Table 45. Global Metabolic Disorder Therapeutics Market Size Market Share Forecast by Region (2026-2031)
Table 46. Global Metabolic Disorder Therapeutics Market Size Forecast by Type (2026-2031) & ($ millions)
Table 47. Global Metabolic Disorder Therapeutics Market Size Forecast by Application (2026-2031) & ($ millions)
Table 48. Novo Nordisk A/S Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 49. Novo Nordisk A/S Metabolic Disorder Therapeutics Product Offered
Table 50. Novo Nordisk A/S Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 51. Novo Nordisk A/S Main Business
Table 52. Novo Nordisk A/S Latest Developments
Table 53. Sanofi S.A. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 54. Sanofi S.A. Metabolic Disorder Therapeutics Product Offered
Table 55. Sanofi S.A. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 56. Sanofi S.A. Main Business
Table 57. Sanofi S.A. Latest Developments
Table 58. Boehringer Ingelheim GmbH Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 59. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product Offered
Table 60. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 61. Boehringer Ingelheim GmbH Main Business
Table 62. Boehringer Ingelheim GmbH Latest Developments
Table 63. Eli Lilly and Company Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 64. Eli Lilly and Company Metabolic Disorder Therapeutics Product Offered
Table 65. Eli Lilly and Company Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 66. Eli Lilly and Company Main Business
Table 67. Eli Lilly and Company Latest Developments
Table 68. Merck KgaA Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 69. Merck KgaA Metabolic Disorder Therapeutics Product Offered
Table 70. Merck KgaA Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 71. Merck KgaA Main Business
Table 72. Merck KgaA Latest Developments
Table 73. Amgen, Inc. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 74. Amgen, Inc. Metabolic Disorder Therapeutics Product Offered
Table 75. Amgen, Inc. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 76. Amgen, Inc. Main Business
Table 77. Amgen, Inc. Latest Developments
Table 78. AstraZeneca PLC Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 79. AstraZeneca PLC Metabolic Disorder Therapeutics Product Offered
Table 80. AstraZeneca PLC Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 81. AstraZeneca PLC Main Business
Table 82. AstraZeneca PLC Latest Developments
Table 83. Actelion Pharmaceuticals Ltd. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 84. Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product Offered
Table 85. Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 86. Actelion Pharmaceuticals Ltd. Main Business
Table 87. Actelion Pharmaceuticals Ltd. Latest Developments
Table 88. Shire PLC Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 89. Shire PLC Metabolic Disorder Therapeutics Product Offered
Table 90. Shire PLC Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 91. Shire PLC Main Business
Table 92. Shire PLC Latest Developments
Table 93. AbbVie, Inc. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 94. AbbVie, Inc. Metabolic Disorder Therapeutics Product Offered
Table 95. AbbVie, Inc. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 96. AbbVie, Inc. Main Business
Table 97. AbbVie, Inc. Latest Developments
Table 98. Biocon Ltd. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 99. Biocon Ltd. Metabolic Disorder Therapeutics Product Offered
Table 100. Biocon Ltd. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 101. Biocon Ltd. Main Business
Table 102. Biocon Ltd. Latest Developments
Table 103. BioMarin Pharmaceutical, Inc. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 104. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product Offered
Table 105. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 106. BioMarin Pharmaceutical, Inc. Main Business
Table 107. BioMarin Pharmaceutical, Inc. Latest Developments
Table 108. Bristol-Myers Squibb Company Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 109. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product Offered
Table 110. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 111. Bristol-Myers Squibb Company Main Business
Table 112. Bristol-Myers Squibb Company Latest Developments
Table 113. Cipla, Inc. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 114. Cipla, Inc. Metabolic Disorder Therapeutics Product Offered
Table 115. Cipla, Inc. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 116. Cipla, Inc. Main Business
Table 117. Cipla, Inc. Latest Developments
Table 118. CymaBay Therapeutics, Inc. Details, Company Type, Metabolic Disorder Therapeutics Area Served and Its Competitors
Table 119. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product Offered
Table 120. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 121. CymaBay Therapeutics, Inc. Main Business
Table 122. CymaBay Therapeutics, Inc. Latest Developments
LIST OF FIGURES
Figure 1. Metabolic Disorder Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Metabolic Disorder Therapeutics Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Metabolic Disorder Therapeutics Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Metabolic Disorder Therapeutics Sales Market Share by Country/Region (2024)
Figure 8. Metabolic Disorder Therapeutics Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Metabolic Disorder Therapeutics Market Size Market Share by Type in 2024
Figure 10. Metabolic Disorder Therapeutics in Oral
Figure 11. Global Metabolic Disorder Therapeutics Market: Oral (2020-2025) & ($ millions)
Figure 12. Metabolic Disorder Therapeutics in Parenteral
Figure 13. Global Metabolic Disorder Therapeutics Market: Parenteral (2020-2025) & ($ millions)
Figure 14. Metabolic Disorder Therapeutics in Others
Figure 15. Global Metabolic Disorder Therapeutics Market: Others (2020-2025) & ($ millions)
Figure 16. Global Metabolic Disorder Therapeutics Market Size Market Share by Application in 2024
Figure 17. Global Metabolic Disorder Therapeutics Revenue Market Share by Player in 2024
Figure 18. Global Metabolic Disorder Therapeutics Market Size Market Share by Region (2020-2025)
Figure 19. Americas Metabolic Disorder Therapeutics Market Size 2020-2025 ($ millions)
Figure 20. APAC Metabolic Disorder Therapeutics Market Size 2020-2025 ($ millions)
Figure 21. Europe Metabolic Disorder Therapeutics Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Metabolic Disorder Therapeutics Market Size 2020-2025 ($ millions)
Figure 23. Americas Metabolic Disorder Therapeutics Value Market Share by Country in 2024
Figure 24. United States Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Metabolic Disorder Therapeutics Market Size Market Share by Region in 2024
Figure 29. APAC Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
Figure 30. APAC Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
Figure 31. China Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 35. India Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Metabolic Disorder Therapeutics Market Size Market Share by Country in 2024
Figure 38. Europe Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
Figure 39. Europe Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
Figure 40. Germany Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 41. France Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Metabolic Disorder Therapeutics Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 54. APAC Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 55. Europe Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 57. United States Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 58. Canada Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 59. Mexico Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 60. Brazil Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 61. China Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 62. Japan Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 63. Korea Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 65. India Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 66. Australia Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 67. Germany Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 68. France Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 69. UK Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 70. Italy Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 71. Russia Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 72. Egypt Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 73. South Africa Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 74. Israel Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 75. Turkey Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 76. Global Metabolic Disorder Therapeutics Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Metabolic Disorder Therapeutics Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 1. Metabolic Disorder Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Metabolic Disorder Therapeutics Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Metabolic Disorder Therapeutics Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Metabolic Disorder Therapeutics Sales Market Share by Country/Region (2024)
Figure 8. Metabolic Disorder Therapeutics Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Metabolic Disorder Therapeutics Market Size Market Share by Type in 2024
Figure 10. Metabolic Disorder Therapeutics in Oral
Figure 11. Global Metabolic Disorder Therapeutics Market: Oral (2020-2025) & ($ millions)
Figure 12. Metabolic Disorder Therapeutics in Parenteral
Figure 13. Global Metabolic Disorder Therapeutics Market: Parenteral (2020-2025) & ($ millions)
Figure 14. Metabolic Disorder Therapeutics in Others
Figure 15. Global Metabolic Disorder Therapeutics Market: Others (2020-2025) & ($ millions)
Figure 16. Global Metabolic Disorder Therapeutics Market Size Market Share by Application in 2024
Figure 17. Global Metabolic Disorder Therapeutics Revenue Market Share by Player in 2024
Figure 18. Global Metabolic Disorder Therapeutics Market Size Market Share by Region (2020-2025)
Figure 19. Americas Metabolic Disorder Therapeutics Market Size 2020-2025 ($ millions)
Figure 20. APAC Metabolic Disorder Therapeutics Market Size 2020-2025 ($ millions)
Figure 21. Europe Metabolic Disorder Therapeutics Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Metabolic Disorder Therapeutics Market Size 2020-2025 ($ millions)
Figure 23. Americas Metabolic Disorder Therapeutics Value Market Share by Country in 2024
Figure 24. United States Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Metabolic Disorder Therapeutics Market Size Market Share by Region in 2024
Figure 29. APAC Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
Figure 30. APAC Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
Figure 31. China Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 35. India Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Metabolic Disorder Therapeutics Market Size Market Share by Country in 2024
Figure 38. Europe Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
Figure 39. Europe Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
Figure 40. Germany Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 41. France Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Metabolic Disorder Therapeutics Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Metabolic Disorder Therapeutics Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Metabolic Disorder Therapeutics Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Metabolic Disorder Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 54. APAC Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 55. Europe Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 57. United States Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 58. Canada Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 59. Mexico Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 60. Brazil Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 61. China Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 62. Japan Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 63. Korea Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 65. India Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 66. Australia Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 67. Germany Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 68. France Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 69. UK Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 70. Italy Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 71. Russia Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 72. Egypt Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 73. South Africa Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 74. Israel Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 75. Turkey Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
Figure 76. Global Metabolic Disorder Therapeutics Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Metabolic Disorder Therapeutics Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Metabolic Disorder Therapeutics Market Size 2026-2031 ($ millions)
More Publications
Global Ursodeoxycholic Acid Market Growth 2025-2031
US$ 3,660.00
August 2025
125 pages
Global Nanoemulsions Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
January 2025
94 pages
Global Notoginseng Root Extract Market Growth 2023-2029
US$ 3,660.00
March 2023
97 pages
Global Lab Automation System Market Growth (Status and Outlook) 2023-2029
US$ 3,660.00
February 2023
100 pages
